Analyst Price Target is $0.00
▼ -100.00% Downside Potential
This price target is based on 0 analysts offering 12 month price targets for cbdMD in the last 3 months. The average price target is $0.00, with a high forecast of $0.00 and a low forecast of $10,000,000.00. The average price target represents a -100.00% upside from the last price of $0.36.
Current Consensus is
N/A
The current consensus among 0 polled investment analysts is to n/a stock in cbdMD. This rating has held steady since September 2024, when it changed from a Buy consensus rating.
cbdMD, Inc. produces and distributes various cannabidiol (CBD) products. The company owns and operates consumer hemp-based CBD brands, such as cbdMD, Paw CBD, hempMD, and cbdMD Botanicals. Its cbdMD brand products include CDB tinctures, gummies, topicals, capsules, drink mixes, and sleep, focus, and calming aids. The company also offers veterinarian-formulated products, including tinctures, chews, and topicals under the Paw CBD brand name; nootropic mushroom line under the ATRx brand; and hemp derived solutions under the hempMD brand. It distributes its products through its e-commerce website, third-party e-commerce sites, select distributors and marketing partners, wholesalers, and various brick and mortar retailers in the United States. The company was formerly known as Level Brands, Inc. and changed its name to cbdMD, Inc. in May 2019. cbdMD, Inc. is headquartered in Charlotte, North Carolina.
Read More
